Grantees Not In Danger Of Losing Cost-Free Biological Materials, But Can’t Have Chemicals
In Brief: NCI Scientists May Run For Congress; Upton Back Heroin For Terminal Cancer Patients
R. Lee Clark to Retire; Texas Starts Search for Successor
Drugs Available To Investigators Centers to Monitor Them Are Listed
FDA’s Young Still Not Satisfied With Distribution Plan
Tobacco Council Announces Awards
FDA Adopts Final Diagnostics X-Ray Rule Amendment
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- The Directors: New directors Herbst and Gius chart a future built on AI, collaboration, and rural access
- FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial - Consumers are increasingly accessing U.S. News rankings of cancer hospitals via AI chatbots
2026 report shows no change in the top-five lineup - What happened at FDA? Replimune approval raises questions









